Ó³»´«Ã½ makes gene editing technologies — including CRISPR-Cas9, Cas12, Cas13, base editing, and prime editing — broadly available. Fields of licensing include internal research use, research tools development, agriculture, animal health, manufacturing, and bioproduction.
We also consider important ethical, safety and societal concerns. In particular, any human clinical use must be consistent with all laws and regulations, and we do not license the technologies for human germline editing.
Since 2014, Ó³»´«Ã½ has executed more than 200 non-exclusive gene editing licenses.